COSMO Pharmaceuticals N.V. (DE:C43)
FRANKFURT:C43
Want to see DE:C43 full AI Analyst Report?
C43 Stock Chart & Stats
€111.80
-€1.00(-1.46%)
At close: 4:00 PM EST
€111.80
-€1.00(-1.46%)
Day’s Range― - ―
52-Week Range€48.80 - €141.00
Previous CloseN/A
Volume64.00
Average Volume (3M)48.00
Market Cap
€1.85B
Enterprise Value€1.64B
Total Cash (Recent Filing)€122.66M
Total Debt (Recent Filing)€4.26M
Price to Earnings (P/E)―
Beta0.69
Next Earnings
Jul 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.10
Shares Outstanding17,543,522
10 Day Avg. Volume20
30 Day Avg. Volume48
Financial Highlights & Ratios
PEG Ratio4.83
Price to Book (P/B)3.74
Price to Sales (P/S)17.21
P/FCF Ratio-113.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€146.40Price Target Upside30.95% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)0.09
Revenue Forecast (FY)€116.07M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetVery low leverage and substantial equity provide durable financial flexibility. This allows Cosmo to fund R&D, support commercialization or licensing initiatives, and absorb revenue or cash-flow volatility without immediate refinancing pressure, preserving strategic optionality over months.
Diversified Commercial ModelA mixed model of direct sales and licensing/milestone/royalty income spreads revenue risk and offers multiple long-term monetization paths. Licensing can deliver non-linear upside with limited incremental cost, while product sales provide recurring demand exposure from clinicians and endoscopy centers.
Demonstrated High-margin PotentialThe company has shown it can generate very high margins and substantial cash in a successful commercial year. That structural profitability potential signals attractive product economics and the ability to fund growth or returns when commercial traction is sustained over time.
Bears Say
Revenue And Profit VolatilityLarge year-to-year swings in revenue and profitability reduce predictability of core earnings and make multi-quarter planning difficult. Such volatility can hinder long-term contracting, raise partner counterparty concerns, and complicate budgeting for R&D and commercial investment.
Deteriorating Cash GenerationA switch to negative operating and free cash flow materially weakens self-funding capacity. Over a multi-month horizon this elevates funding risk for development and commercialization, increasing reliance on balance-sheet reserves or external financing despite low leverage.
Inconsistent Historical EarningsRepeated periods of losses interspersed with strong years indicate limited revenue visibility and execution inconsistency. For investors and partners, this undermines confidence in steady cash generation and complicates long-term forecasting and strategic partnerships.
COSMO Pharmaceuticals N.V. News
C43 FAQ
What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?
COSMO Pharmaceuticals N.V. lowest stock price was €48.80 and its highest was €141.00 in the past 12 months.
What is COSMO Pharmaceuticals N.V.’s market cap?
COSMO Pharmaceuticals N.V.’s market cap is €1.85B.
When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?
COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 29, 2026 which is in 103 days.
How were COSMO Pharmaceuticals N.V.’s earnings last quarter?
COSMO Pharmaceuticals N.V. released its earnings results on Mar 09, 2026. The company reported -€0.1 earnings per share for the quarter, missing the consensus estimate of €0.2 by -€0.3.
Is COSMO Pharmaceuticals N.V. overvalued?
According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued.
Does COSMO Pharmaceuticals N.V. pay dividends?
COSMO Pharmaceuticals N.V. does not currently pay dividends.
What is COSMO Pharmaceuticals N.V.’s EPS estimate?
COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does COSMO Pharmaceuticals N.V. have?
COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.
What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?
COSMO Pharmaceuticals N.V. reported an EPS of -€0.1 in its last earnings report, missing expectations of €0.2. Following the earnings report the stock price went down -9.483%.
Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?
Currently, no hedge funds are holding shares in DE:C43
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
COSMO Pharmaceuticals N.V.
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
C43 Stock 12 Month Forecast
Average Price Target
€146.40
▲(30.95% Upside)
Technical Analysis
Options Prices
Currently, No data available
---